Preventive effect of Bacillus mojavensis levan against carbon tetrachloride and cisplatin toxicity: in vivo study
This study is the first to investigate the hepato- and nephron-preventive effect of levan from Bacillus mojavensis (BM-levan) against toxicity induced by carbon tetrachloride (CCl 4 ) and cisplatin. Thirty-six male albino rats weighing between 230 and 250 g were used for this experiment. The groups...
Uložené v:
| Vydané v: | Environmental science and pollution research international Ročník 28; číslo 36; s. 50117 - 50126 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.09.2021
Springer Nature B.V |
| Predmet: | |
| ISSN: | 0944-1344, 1614-7499, 1614-7499 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | This study is the first to investigate the hepato- and nephron-preventive effect of levan from
Bacillus mojavensis
(BM-levan) against toxicity induced by carbon tetrachloride (CCl
4
) and cisplatin. Thirty-six male albino rats weighing between 230 and 250 g were used for this experiment. The groups received multiples doses of BM-levan and were compared to the untreated group. The in vitro and in vivo biological potentials of BM-levan were evaluated by measuring its antioxidant capacity as well as its hepato- and nephron-protective activities in rat models. The investigations highlighted a significant in vitro antioxidant activity indicated by the radical-scavenging capacity, the reducing power, and the total antioxidant activity measurement. In addition, results demonstrate that BM-levan supplementation during 8 weeks (100 mg/kg body weight) significantly (
p < 0.05
) decreased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities and remarkably (
p < 0.05
) attenuated the altered lipid profile by decreasing the levels of triglycerides (TG) and total cholesterol (TC), LDL cholesterol (LDL-C) and by enhancing the HDL cholesterol (HDL-C) content, when compared with the CCl
4
group. BM-levan also reduced the content of plasma renal biomarkers (urea, creatinine, and uric acid) in the cisplatin-treated group. Moreover, BM-levan inhibited hepatic and renal oxidative stress generated by CCl
4
and cisplatin administration, through the enhancement of the antioxidant catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) and the diminishment of lipid peroxidation. The harmful effects of CCl
4
or cisplatin on hepatic and renal histology were found to be decreased by the addition of BM-levan. Therefore, BM-levan has proved promising for biomedical applications thanks to its in vitro and in vivo antioxidant properties. |
|---|---|
| Bibliografia: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 0944-1344 1614-7499 1614-7499 |
| DOI: | 10.1007/s11356-021-14147-3 |